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Telomere maintenance by telomerase is impaired in
the stem cell disease dyskeratosis congenita and
during human aging. Telomerase depends upon a
complex pathway for enzyme assembly, localization
in Cajal bodies, and association with telomeres.
Here, we identify the chaperonin CCT/TRiC as a crit-
ical regulator of telomerase trafficking using a high-
content genome-wide siRNA screen in human cells
for factors required for Cajal body localization. We
find that TRiC is required for folding the telomerase
cofactor TCAB1, which controls trafficking of telo-
merase and small Cajal body RNAs (scaRNAs).
Depletion of TRiC causes loss of TCAB1 protein, mis-
localization of telomerase and scaRNAs to nucleoli,
and failure of telomere elongation. DC patient-
derived mutations in TCAB1 impair folding by TRiC,
disrupting telomerase function and leading to severe
disease. Our findings establish a critical role for
TRiC-mediated protein folding in the telomerase
pathway and link proteostasis, telomere mainte-
nance, and human disease.
INTRODUCTION
Telomeres are nucleoprotein structures that protect chromo-
some ends and serve as substrates for the enzyme telomerase
(Palm and de Lange, 2008). Telomeres shorten progressively
with cell division due to incomplete replication of the lagging
DNA strand, and this shortening is offset by processive elonga-
tion of telomeres by telomerase (Pfeiffer and Lingner, 2013).
Impairedmaintenance of telomeres contributes to the pathogen-
esis of many disease states, including dyskeratosis congenita,
pulmonary fibrosis, aplastic anemia, and liver cirrhosis (Arma-
nios and Blackburn, 2012). Conversely, effective maintenance
of telomeres by telomerase is thought to be important in progres-
sion of human cancers (Artandi and DePinho, 2010; Hahn et al.,1999; Horn et al., 2013; Huang et al., 2013; Killela et al., 2013).
The telomerase ribonucleoprotein requires a complex series of
biochemical steps to enable enzymatic function at telomeres. Ef-
forts to develop telomerase therapeutics useful in diverse dis-
eases require a more complete understanding of these steps
and the molecules that govern them. Unbiased approaches to
identify telomerase regulators in human cells have thus far
been limited by difficulty in detecting telomerase components,
precluding the development of genetic screens to interrogate
this pathway.
Active telomerase enzyme is comprised of a catalytic core—
the telomerase RNA component, TERC, and the telomerase
reverse transcriptase, TERT—in addition to several additional
proteins required for proper telomerase function. The biogenesis
of functional telomerase is mediated by a series of maturation,
assembly, and trafficking steps that take place within the nu-
cleus, as well as within Cajal bodies—subnuclear structures
devoted to RNA modification and assembly (Egan and Collins,
2012). Human TERC shares sequence motifs in common with
small Cajal body RNAs (scaRNAs), which act as guides for post-
transcriptional modification of splicing RNAs within Cajal bodies
(Darzacq et al., 2002; Ja´dy et al., 2004; Zhu et al., 2004). The pro-
cesses regulating telomerase assembly overlap considerably
with biogenesis pathways for scaRNAs and related small nucle-
olar RNAs (snoRNAs), all of which share an H/ACA sequence
recognized by the dyskerin core complex—dyskerin, NHP2,
and NOP10. TERC stability is dependent on the dyskerin core
complex and on the assembly factors NAF1, Shq1, and pontin/
reptin (Egan and Collins, 2012). Incorporation of TERT protein
into an RNP containing TERC and the dyskerin core complex
yields a telomerase enzyme that is stable and catalytically active
(Cohen et al., 2007; Mitchell et al., 1999).
After these initial stages of assembly, telomerase localizes to
Cajal bodies by association with TCAB1, which recognizes the
CAB box sequence common to TERC and scaRNAs (Cristofari
et al., 2007; Tycowski et al., 2009; Venteicher et al., 2009). Telo-
merase is specifically recruited to telomeres through an interac-
tion between TERT and the oligonucleotide/oligosaccharide
binding (OB) fold of the telomere binding protein TPP1 (Abreu
et al., 2010; Nandakumar et al., 2012; Sexton et al., 2012; ZhongCell 159, 1389–1403, December 4, 2014 ª2014 Elsevier Inc. 1389
et al., 2012), and this step requires TCAB1 (Stern et al., 2012;
Zhong et al., 2012). TCAB1 is required for trafficking of telome-
rase to Cajal bodies and for telomere maintenance (Venteicher
et al., 2009). This requirement is highlighted by the existence of
TCAB1 mutations in patients with dyskeratosis congenita (DC),
a stem cell disease caused by a failure of telomere maintenance
(Zhong et al., 2011). DC is characterized by an epidermal triad
(oral leukoplakia, nail dystrophy, and skin pigmentation abnor-
malities), bonemarrow failure, pulmonary fibrosis, and increased
cancer (Armanios and Blackburn, 2012). Mutations in DC target
each of the known components of telomerase and interfere with
many steps in the telomerase pathway, including assembly, traf-
ficking, recruitment to telomeres, and catalytic activity (Batista
and Artandi, 2013). TCAB1 mutations occur in an autosomal
recessive form of DC, in which single amino acid substitutions
in TCAB1 protein cause a marked reduction in protein accumu-
lation and disruption of telomerase localization fromCajal bodies
to nucleoli (Zhong et al., 2011). Mislocalization of telomerase to
nucleoli causes telomere shortening and DC; however, the
mechanism by which these mutations disrupt TCAB1 function
is not understood.
Nascent polypeptides must navigate a complex thermody-
namic and kinetic landscape to acquire and maintain their
native, functional form. Coordinating this process across all
the proteins in the cell requires a highly organized proteostasis
network that regulates protein biogenesis, conformational main-
tenance, and degradation (Kim et al., 2013; Wolff et al., 2014).
For many proteins, proper folding and function requires stabili-
zation of folding intermediates, a process performed by molec-
ular chaperones, which derive from one of several classes,
including HSP70, HSP90, and chaperonins. Responsible for
the vast majority of chaperone-mediated folding within the
cell, the HSP70 and HSP90 systems tend to act as monomers
or homodimers to bind sections of nascent polypeptides, stabi-
lizing regions of hydrophobicity until the polypeptides can prop-
erly fold. In contrast, chaperonins form barrel-like cages in which
individual polypeptides are encapsulated, allowing folding to
proceed isolated from the general cellular environment (Horwich
et al., 2007).
As a general rule, fast-folding proteins are stabilized by the
HSP70 and HSP90 systems, whereas difficult-to-fold proteins
are transferred to the chaperonin system. TRiC (TCP-1 Ring
Complex) is a large group II chaperonin complex containing eight
homologous subunits arranged in two stacked, octameric rings.
TRiCwas originally identified based on its essential role in folding
the cytoskeletal proteins actin and tubulin (Frydman et al., 1992;
Gao et al., 1992). Approaches to identify novel TRiC substrates
suggest that its substrates are more numerous, although only a
restricted set of proteins out of the thousands that flux through
the proteostasis network depend on TRiC for their biogenesis
(Yam et al., 2008). The primary function of TRiC is to participate
in the folding of newly synthesized polypeptides, as opposed to
the refolding of stress-denatured proteins; consequently, unlike
other arms of the proteostasis network, TRiC expression is
linked to protein synthesis and is not induced by stress (Alba-
ne`se et al., 2006). TRiC has been shown to inhibit polyglutamine
aggregation and thus may have neuroprotective properties
regarding the development of age-related misfolding diseases1390 Cell 159, 1389–1403, December 4, 2014 ª2014 Elsevier Inc.such as Huntington’s disease (Behrends et al., 2006; Kitamura
et al., 2006; Tam et al., 2006).
In this study, we deploy a genetic screen to identify regulators
of telomerase trafficking using a genome-wide, high-content,
RNA fluorescence in situ hybridization (FISH)-based siRNA
screen in human cells. The screen identified subunits of the
chaperonin TRiC, and we demonstrate an essential role for
TRiC in telomerase function and trafficking of telomerase and
scaRNAs to Cajal bodies. These effects are due to the essential
role of TRiC in folding TCAB1, and we find that DC patient muta-
tions in TCAB1 disrupt this critical step in TCAB1 biogenesis,
providing a molecular explanation for these cases of human dis-
ease. These findings reveal important connections linking pro-
teostasis pathways to telomerase function and telomere disease
states.
RESULTS
TRiC Is a Recurrent Hit in a Genetic Screen for
Regulators of Telomerase Trafficking
The application of a genetic screen interrogating the telomerase
trafficking pathway has potential to identify new regulators of
telomerase. However, low expression of the telomerase catalytic
core, TERT and TERC, has precluded the development of such
assays. To overcome these limitations, we designed and per-
formed a genome-wide, high-content siRNA screen for genes
required for localization of TERC and TCAB1 in Cajal bodies.
To capture a sufficient population of cells, we acquired all im-
ages at 2003 magnification. Although endogenous TERC foci
were readily detectable at higher magnifications (i.e., 6303), 200
3 magnification was insufficient to resolve individual foci (Fig-
ure S1A available online); instead, we generated clonal HeLa
S3 cells stably overexpressing TERC at levels 9-fold higher
than endogenous TERC (Figure S1B). Overexpressed TERC
was readily detectable in foci at 2003 (Figures S1A and S1B)
and retained its dependence on dyskerin and TCAB1 for locali-
zation to Cajal bodies, validating the utility of this approach
(Figure S1C).
Using a human siRNA library containing 21,121 siRNA pools (4
siRNAs per pool), each targeting a single gene, we reverse trans-
fected TERC-expressing HeLa S3 cells in 384-well optical plates
in triplicate (Figure 1A). Cells were fixed, and immunofluores-
cence was performed for coilin, a Cajal body marker, and
TCAB1 using antibodies against each endogenous protein, fol-
lowed by RNA FISH for TERC. Images of a single field in each
well (100 cells) were captured robotically, and images were
loaded into an analysis pipeline, which automatically identified
nuclei, coilin foci, TCAB1 foci, and TERC foci. For each image,
we calculated a localization score—the fraction of foci pixels in
the TERC or TCAB1 image that were also foci in the coilin image,
i.e., foci overlap using coilin as the baseline. Scores were nor-
malized to negative controls to calculate ‘‘localization inhibition,’’
with 0% indicating no TERC or TCAB1 disruption and 100% rep-
resenting complete lack of TERC or TCAB1 in Cajal bodies (see
Figure 1B for example images). For TERC and TCAB1, the
average Z0-factors across all plates were 0.68 and 0.81, respec-
tively, well above the conventional 0.5 value that designates an
assay amenable to large-scale screening (Figure S1D) (Zhang
Figure 1. TRiC Is a Recurrent Hit in a Genetic Screen for Regulators of Telomerase Trafficking
(A) High-content screening workflow. Reverse transfection of HeLa cells into 384-well plates with siRNA pools targeting individual genes, stained for Coilin,
TCAB1, and TERC and imaged at 2003 to determine overlap between the Coilin and TERC or TCAB1 channels. Heat map of data from one plate; well color
indicates localization score. Yellow, localization; blue, no localization.
(B) Representative screen images for negative control and positive control (Dyskerin siRNA) images, shown with percent localization inhibition.
(C) Graphical representation of screen data. y axis, percent inhibition of TERC localization to Cajal bodies. x axis, dimensionless. Red dots, positive control wells
(siDKC1; n = 1,608). Blue dots, negative control wells (siNon-targeting; n = 1,608). Black line represents the median value (of triplicates) from each siRNA pool in
ascending order (n = 21,119). Yellow dots show siRNA pools targeting CCT/TRiC genes. Dashed line, three SD cutoff.
(D) Localization inhibition for known telomerase components and biogenesis factors (black) and TRiC subunits called as hits (red). All called as hits except those
marked by an asterisk.et al., 1999). Whereas positive control dyskerin siRNA wells
(eight per plate, n = 1,608) yielded amedian TERC localization in-
hibition of 99.6%, the median TERC inhibition of all the experi-
mental siRNAs was 0.3% with a SD of 22.4%, demonstratingthat the vast majority of experimental siRNAs had no effect on
TERC localization to Cajal bodies (Figure S1C). After removing
toxic siRNAs and coilin-eliminating siRNAs and applying a hit
cutoff of three SDs above the mean (corresponding to 67.3%Cell 159, 1389–1403, December 4, 2014 ª2014 Elsevier Inc. 1391
inhibition), we found that 119 siRNA pools qualified as TERC in-
hibition hits (Figure 1C). Hits included virtually all known compo-
nents of the H/ACA box snoRNP complex, which is required for
TERC biogenesis: DKC1, NHP2, NOP10, NAF1, and SHQ1 (Fig-
ure 1D). Hits also included TCAB1 and the telomerase assembly
factors Pontin and Reptin. TERT siRNAs had no effect on TERC
localization, which may be a consequence of poor knockdown.
In addition to these known telomerase biogenesis and assembly
factors, which validate the screening approach, hits included
four members of TRiC: CCT8, CCT4, CCT7, and CCT6A (Fig-
ure 1D). Two other TRiC members fell just below the hit cutoff:
CCT1 and CCT2 (Figure 1C). CCT6B siRNAs had no effect,
which was expected as its expression is restricted to testicular
tissues (Kubota et al., 1997). In the primary screen, CCT3 and
CCT5 also showed no effect, which we subsequently deter-
mined were false negatives (see Figure S2A). Analyzing the
TCAB1 channel in a similar manner, we found that TRiC subunits
were also required for TCAB1 localization to Cajal bodies (Fig-
ure S1F), demonstrating that multiple telomerase components
were perturbed due to TRiC depletion.
TRiC Is Required for TERC and scaRNA Trafficking
To validate and expand these results at a conventional scale, we
depleted TRiC components in HeLa cells using RNA interference
and assessed TERC localization at high magnification. Depletion
of TRiC subunits led to mislocalization of endogenous TERC to
nucleoli, results indistinguishable from depletion of TCAB1 itself
(Figures 2A and 2D) (p < 0.001 by Fisher’s exact test). In contrast,
depletion of dyskerin (DKC1) resulted in a global reduction in
TERC signal, which is consistent with the function of dyskerin
in TERC stability and assembly. Unlike depletion of dyskerin,
neither TCAB1 depletion nor depletion of any TRiC subunit
reduced TERC level measured by northern blot (Figure 2B).
Localization of TERC stably overexpressed in HeLa cells was
similarly dependent on TRiC, as depletion of any TRiC subunit
led tomislocalization to nucleoli, demonstrating that overexpres-
sion of TERC cannot compensate for TRiC loss (Figure S2A). To
test whether TRiC was required more generally for localization of
scaRNAs in Cajal bodies, we used FISH to examine trafficking of
scaRNAs containing either an H/ACA box only (U93) or an H/ACA
box and a C/D box (U85 and U87). In all cases, we found that
TRiC knockdown resulted in partial mislocalization of these
scaRNAs to nucleoli to a degree that phenocopied TCAB1
knockdown (Figures 2C, 2D, S2B, and S2C) (p < 0.001 by
Fisher’s exact test). These data demonstrate that TRiC is
required for the proper localization of TERC, as well as multiple
scaRNAs, to Cajal bodies.
Telomerase Recruitment and Telomere Addition
Depend upon TRiC
Association between TERC and TCAB1 is required for telome-
rase to localize to Cajal bodies and, subsequently, for telome-
rase to localize to telomeres (Cristofari et al., 2007; Stern
et al., 2012; Venteicher et al., 2009; Zhong et al., 2011, 2012).
To assess telomerase at telomeres, we overexpressed both
telomerase RNA component (TERC) and hemagglutinin antigen
(HA)-tagged TERT in HeLa cells, which causes ectopic telome-
rase to localize to telomeres in a high proportion of cells (Cristo-1392 Cell 159, 1389–1403, December 4, 2014 ª2014 Elsevier Inc.fari and Lingner, 2006; Zhong et al., 2012). We visualized the
colocalization of HA-TERT and telomeres by immunofluores-
cence using anti-HA antibodies and antibodies against the
telomere-binding protein TRF2 (Figure 3A). Telomerase was effi-
ciently recruited to telomeres in control cells, whereas siRNA-
mediated depletion of DKC1 or TCAB1 strongly decreased
that recruitment. Depletion of TRiC subunits significantly re-
duced the average frequency of telomerase foci at telomeres
from 15 HA-TERT foci at telomeres in control cells to 2–4 in
TRiC-depleted cells (p < 0.0001, Student’s t test) (Figure 3B).
Thus, recruitment of telomerase to telomeres—a rate-limiting
step in telomere synthesis—is exquisitely dependent on the
TRiC complex.
To determine whether telomere addition requires TRiC, we
employed an assay that allows direct visualization of newly
added telomere repeats, programmed by a TERC variant con-
taining a mutant template region (Diolaiti et al., 2013). When ex-
pressed in HeLa cells for 3 days, this mutant TERC (TSQ1),
together with endogenous TERT and other telomerase cofac-
tors, efficiently mediated addition of variant GTTGCG repeats
that were visualized by combined DNA FISH for the mutant se-
quences and for natural telomere repeats (TTAGGG) (Figure 3C).
Control cells contained an average of approximately ten telo-
meres per cell with detectable GTTGCG signal, demonstrating
that telomere elongation occurred at these telomeres over the
4 day period (Figure 3D). Depletion of TRiC subunits, DKC1, or
TCAB1 using siRNA strongly decreased addition of new repeats
to fewer than three telomeres per cell, indicating that TRiC is
required for telomere synthesis. Together, these data show
that loss of TRiC leads to mislocalization of telomerase to
nucleoli, inhibits telomerase recruitment to telomeres, and pre-
vents telomere addition by telomerase.
TRiC Interacts with the TCAB1 WD40 Domain and Is
Required for TCAB1 Accumulation
The similar requirements for TCAB1 and TRiC in telomerase
localization, recruitment to telomeres, and telomere synthesis,
together with the observation that TRiC knockdown led to
reduced TCAB1 foci in our genetic screen (Figure S1F), led us
to hypothesize that the requirement for TRiC in telomerase func-
tionwas based upon a role for TRiC in TCAB1 biogenesis. To test
this idea, we depleted TRiC subunits in HeLa S3 cells and moni-
tored TCAB1 foci by immunofluorescence and overall TCAB1
levels by western blot. Depletion of any of the eight TRiC sub-
units with siRNA strongly diminished TCAB1 foci (Figures 4A
andS3A) andmarkedly reduced TCAB1protein levels (Figure 4B)
without altering TCAB1 mRNA levels (Figure S3B). Each CCT
siRNA led to codepletion of specific subsets of CCT proteins,
likely reflecting patterns of codependence of CCT components
within the TRiC complex (Figure 4B). To determine the selectivity
of this TRiC-TCAB1 relationship, we depleted two Hsp70 family
molecular chaperones: HSPA8 (Hsc70) and HSPA5 (GRP-78),
both of which are required for the proper folding of a diverse
set of cytoplasmic proteins (Liu et al., 2012). Depletion of these
Hsp70 family chaperones had no effect on TCAB1 protein accu-
mulation (Figure S3C), showing that disruption of TCAB1 is a
TRiC-specific response rather than a result of general protein
folding disruption.
Figure 2. TRiC Is Required for TERC and scaRNA Trafficking
(A) RNA FISH for TERC (red) and IF for coilin (green) in HeLaS3 cells transfected with indicated siRNAs. DAPI, blue. Arrows indicate nucleolar staining.
(B) Northern blot for TERC in HeLa S3 cells transfected with indicated siRNAs; 18S rRNA, loading control.
(C) RNA FISH for U85 (red) and IF for coilin (green) in HeLaS3 cells transfected with indicated siRNAs. DAPI, blue. Arrows indicate nucleolar staining.
(D) Quantification of nucleolar staining for TERC, U85, U87, and U93 scaRNAs from (A) and (C) and Figures S2B and S2C. 150 cells analyzed per condition, p <
0.001 for either TCAB1 siRNAs or each CCT siRNAs versus siNon-targeting controls, Fisher’s exact test.To determine whether TCAB1 and TRiC interact, we puri-
fied TCAB1 complexes through dual-affinity chromatography
coupled with mass spectrometry (MS). TCAB1 tagged at its N
terminus with Staph Protein A, a TEV cleavage site, and three
HA epitopes (AH3-TCAB1) was stably expressed in HeLa S3
cells by retroviral transduction, purified on rabbit IgG, eluted
with TEV protease, captured again using anti-HA resin, and
then eluted, fractionated by SDS-PAGE, and analyzed using
nano-liquid chromatography-tandem MS (nanoLC-MS/MS).
High peptide coverage was obtained for TCAB1, for the
TCAB1-associated protein dyskerin, and for all eight subunits
of the TRiC complex (Figure 4C). Immunoprecipitation of endog-enous TCAB1 using TCAB1 polyclonal antibodies effectively
depleted HeLa cell extracts of TCAB1 protein and revealed
endogenous CCT1 and CCT2 in association with TCAB1 (Fig-
ure 4D). Pull-down of TCAB1 did not deplete CCT1 or CCT2, indi-
cating that only a small fraction of TRiC is associatedwith TCAB1
(Figure 4D). These findings show that TCAB1 and TRiC associate
at the endogenous level and suggest a substoichiometric or tran-
sient association.
The predicted structure of TCAB1 includes an unstructured
N-terminal region, a WD40 domain with seven WD40 repeats
forming a b propeller—a protein structure with complex topology
and multiple regions of hydrophobicity—followed by a shortCell 159, 1389–1403, December 4, 2014 ª2014 Elsevier Inc. 1393
Figure 3. Telomerase Recruitment and
Telomere Addition Depend upon TRiC
(A) Colocalization of HA-TERT and TRF2 by IF
in cells transfected with indicated siRNAs and
HA-TERT and TERC plasmids.
(B)QuantificationofHA-TERTat telomeres from (A).
150 cells analyzed per condition. Mean ± SEM, p <
0.0001 for each siRNA versus siNon-targeting
control by two-tailed Student’s t test.
(C) FISH for incorporation of mutant telomeres
(GTTGCG) and FISH for wild-type telomere se-
quences (TTAGGG) in HeLa S3 cells transfected
with indicated siRNAs and mutant TERC (TSQ1).
(D) Quantification of GTTGCG foci at telomeres
(TTAGGG foci) from (C). 150 cells analyzed per
condition. Mean ± SEM, p < 0.0001 for each
siRNA versus siNon-targeting control by two-
tailed Student’s t test.C-terminal extension (Figure 4E). Analysis of a series of N-termi-
nal deletion mutants of TCAB1 revealed that the WD40 domain
and theC-terminal extensionwere sufficient for TRiC association
and for Cajal body localization in HeLa cells (Figures S3D and
S3E). Further impingement on the WD40 domain or deletion of
the short C-terminal extension prevented accumulation in hu-
man cells (data not shown); therefore, we expressed additional
mutant proteins in rabbit reticulocyte lysate (RRL), an extract
that enables translation and folding but lacks active protein
degradation machinery. Deletion of the C-terminal region (DC,
deletion of residues 510–548) resulted in efficient translation
and an enhanced association with rabbit TRiC in the extract by
coimmunoprecipitation (co-IP) (Figure 4E). Expression of the
WD40 domain alone (residues 126–509, WD40) resulted in low
levels of this isolated domain but in significantly greater binding1394 Cell 159, 1389–1403, December 4, 2014 ª2014 Elsevier Inc.to TRiC compared to full-length TCAB1.
These data show that the WD40 domain
of TCAB1 mediates association with
TRiC but that stabilization of TCAB1 and
efficient release from TRiC also require
the C-terminal region of TCAB1.
To determine which TCAB1 sequences
are involved in binding TERC, we per-
formed IP-northern assays in RRL with
FLAG-tagged TCAB1 mutant proteins
after adding in-vitro-transcribed TERC.
In validation studies, the association be-
tween wild-type TCAB1 and TERC in
this assay was dependent upon an intact
CAB box, as either of two inactivating
mutations in the CAB box, m1-UGAc or
m2-UcAG (Cristofari et al., 2007; Ja´dy
et al., 2004), markedly diminished bind-
ing to TCAB1 (Figure S3F). Full-length
TCAB1 and DN125 bound wild-type
TERC similarly well, but association be-
tween DC and WD40 fragments of
TCAB1 with TERC was greatly reduced
(Figure 4E). These data suggest that theWD40 domain, together with the short C-terminal extension,
may comprise a single functional domain that both binds TERC
and depends upon TRiC for folding.
TRiC Is Required to Fold TCAB1, Enabling TCAB1
to Bind TERC
Although the kinetics of dissociation vary by substrate, TRiC
clients are only transiently associated with the complex and
are released after folding is complete. To determine whether
TCAB1 is a TRiC substrate, we in vitro translated TCAB1 or yeast
actin as a positive control in the presence of 35S-methionine in
RRL. After the initial labeling, reactions were chased with cold
methionine for the indicated number of hours, and proteins
were fractionated by native PAGE. Actin is a known substrate
of TRiC and is folded in a TRiC-dependent manner in RRL
(Gao et al., 1992). Migration of newly synthesized yeast actin was
retarded in the gel, whereas after a 1 hr chase, actin migrated
more rapidly, which is consistent with being released from
TRiC (Vainberg et al., 1998) (Figure 5A). In-vitro-translated
TCAB1 similarly migrated in two forms. Newly translated
TCAB1 protein was detected almost exclusively in a slow
migrating species that comigrated with newly synthesized actin.
Over a 4 hr chase period, TCAB1 became rapidly migrating and
formed a discrete lower band. We verified that both radiolabeled
species were in fact TCAB1 by translating FLAG-TCAB1 and
performing a western blot after native PAGE (Figure S4A).
TRiC, visualized by CCT2 western blotting, comigrated with
the retarded, newly synthesized form of TCAB1 in RRL (Fig-
ure S4A). We showed that the upper TCAB1 band was TRiC
bound by immunodepleting CCT2 after TCAB1 translation (Fig-
ure S4B), leading to a significant decrease in the upper bands
of both yeast actin and TCAB1 while preserving the lower bands
for both proteins (Figure 5B). These results demonstrate that
TCAB1 polypeptides are bound by TRiC during or soon after
translation and are released from association with TRiC over
time.
We hypothesized that TRiC released TCAB1 once folding was
complete. Partial resistance to protease digestion is a character-
istic of many correctly folded, compact proteins (Frydman et al.,
1994). To optimize this approach for natively folded TCAB1, we
performed a dose response proteinase K (PK) digestion on
HeLa lysate and analyzed protease-resistant TCAB1 fragments
by western blotting (Figure S4C). Partial PK digestion at 1.2 mg/
ml generated two protease-resistant TCAB1 bands between
37 and 50 kDa, whereas higher concentrations degraded the
protein completely and lower concentrations had no effect. We
then examined the protease resistance of in-vitro-translated
TCAB1 before and after TRiC-release to assess whether TRiC
binding caused TCAB1 to adopt a similarly protease-resistant
structure. PK degraded all protein at zero hr but resulted in a
protected species at 4 hr, characterized by two discrete prote-
ase-resistant TCAB1 bands (Figure 5C) similar in size to those
generated by partial digestion of cellular TCAB1 (Figure S4C).
Importantly, the input of total TCAB1 protein treated with PK
was comparable at both time points (Figure 5C, bottom). These
data indicate that TCAB1 is partially resistant to protease treat-
ment only after being released from TRiC, suggesting that this
TRiC-released TCAB1 species is compact and correctly folded.
To understand whether TRiC is required for folding TCAB1, we
immunodepleted TRiC from RRL using antibodies to CCT2 and
then reconstituted the complex to endogenous levels using pu-
rified bovine TRiC or usedmock depletion with IgG as a negative
control (Figure 5D). Proteins were then synthesized under TRiC-
depleted and TRiC-add-back conditions. Translation of either
yeast actin or TCAB1 in TRiC-depleted RRL resulted in a marked
reduction of both the TRiC-associated form (>50% reduction
versus mock-depleted controls) and the folded species for
each protein (>90% reduction versus mock-depleted controls)
by native PAGE (Figures 5E and S4D). Add-back of bovine
TRiC to the depleted RRL restored both the TRiC-bound
(>100% versus mock-depleted controls) and folded species
(>50% versus mock-depleted controls) of actin and TCAB1 (Fig-
ures 5E and S4D). Depletion of TRiC, or TRiC add-back, did notsignificantly change the overall amount of translated proteins by
SDS-PAGE (Figure 5E, bottom). These data show that TRiC is
required for TCAB1 to be folded to a compact, rapidly migrating
conformation in RRL.
TCAB1 associates with TERC and with scaRNAs by binding
the CAB box sequence common to these RNAs (Tycowski
et al., 2009; Venteicher et al., 2009). To understand whether
TRiC-mediated folding is required for TCAB1 to associate with
TERC, we tested the effects of TRiC depletion in RRL on
TCAB1-TERC binding by IP-northern (Figure 4). TCAB1 trans-
lated in TRiC-depleted RRL bound <10% of the TERC bound
by TCAB1 translated in mock-depleted RRL (Figures 5F and
S4E). Add-back of bovine TRiC to TRiC-depleted extracts
restored the ability of TCAB1 to associate with TERC to >60%
of mock-depleted level (Figures 5F and S4E). Taken together,
these data demonstrate that TCAB1 is an obligate TRiC sub-
strate, requiring TRiC for folding and TERC binding, and that
loss of TRiC cannot be compensated by the presence of other
chaperones.
Disruption of TRiC-Mediated Folding Underlies the
Defects in the TCAB1 Mutant Form of DC
The effects of TRiC depletion on the telomerase pathway—
diminished TCAB1 protein, loss of TERC and TCAB1 from Cajal
bodies, and a failure of telomere synthesis—closely resembled
the underlying features of a form of DC caused by compound
heterozygous mutations in TCAB1 (Zhong et al., 2011). For
each of four identified disease-causing alleles, missense muta-
tions in TCAB1 were located in or near loop regions within the
WD40 domain, the principal substrate for TRiC-mediated folding
(Figure 6A). We therefore hypothesized that the single amino
acid mutations in TCAB1 specifically disrupted folding of
TCAB1 by TRiC. TCAB1 protein levels were markedly reduced
in Epstein-Barr virus (EBV)-transformed lymphoblasts derived
from two DC patients with compound heterozygous TCAB1
mutations, compared to levels in unrelated individuals with
wild-type TCAB1 (Figure 6B). Furthermore, each of the mutant
TCAB1 alleles also showed impaired protein accumulation
when stably overexpressed in HeLa cells, indicating that dimin-
ished expression is an intrinsic property of the mutant proteins
and is not related to mRNA level (Figures 6B and S5A). Consis-
tent with diminished expression, TCAB1 protein failed to localize
properly to Cajal bodies, both in patient lymphoblasts (Figure 6C)
and in stably transduced HeLa cells in which TCAB1 was de-
tected in the cytoplasm (Figure S5B), where TRiC resides almost
exclusively (Figure S5C) (Zhong et al., 2011).
To determine whether DC-derived TCAB1 mutants fail to
accumulate because of a defect in folding by TRiC, we assessed
the resistance to protease digestion of mutant versus wild-type
TCAB1 in patient-derived lymphoblasts. As in HeLa cells and
RRL, wild-type TCAB1 in lymphoblasts displayed two prote-
ase-resistant bands between 50 and 37 kDa; however, mutant
TCAB1 in DC-patient-derived lymphoblasts showed no resis-
tance to protease treatment under the same conditions (Fig-
ure S5D). Mutant TCAB1 accumulated to lower levels than
wild-type TCAB1, raising the possibility that the difference in
protease resistance was due to a difference in total protein level.
We therefore examined DC-derived TCAB1 mutants versusCell 159, 1389–1403, December 4, 2014 ª2014 Elsevier Inc. 1395
Figure 4. TRiC Interacts with the TCAB1 WD40 Domain and Is Required for TCAB1 Accumulation
(A) IF for TCAB1 (red) and coilin (green) in HeLa S3 cells transfected with siRNAs against TCAB1 and CCT1. DAPI, blue.
(B) Western blot for TCAB1 and TRiC subunits in HeLa S3 cells transfected with siRNAs against eight TRiC subunits; GAPDH, loading control.
(legend continued on next page)
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wild-type TCAB1 expressed in RRL, where the mutant and wild-
type TCAB1 proteins accumulate at comparable levels (Fig-
ure 6D, bottom). Unlike wild-type TCAB1, which was partially
protected from PK digestion at 4 hr, each DC-derived TCAB1
mutant failed to show PK resistance at 4 hr (Figure 6D, top). To
determine whether this inability to fold properly corresponded
to differences in TRiC binding or release, TCAB1 proteins were
assayed after pulse-chase in RRL by native PAGE. In-vitro-trans-
lated TCAB1 mutants were initially bound by TRiC to the same
degree as wild-type TCAB1, but whereas wild-type TCAB1
was released after several hours, the TCAB1 mutants remained
TRiC associated and were impaired in progression to the
compact, rapidly migrating form (Figure 6E; see Figure 6D for
loading). We assessed whether this impaired folding of the
DC-derived TCAB1 mutants affected their ability to bind TERC.
Compared with wild-type TCAB1, in-vitro-translated TCAB1
mutants showed a marked decrease in TERC association by
IP-northern (Figure 6F). These data show that DC-associated
TCAB1 mutants cannot be properly folded by TRiC, show
enhanced TRiC association, and are impaired in their ability to
bind TERC.
The increased association of TCAB1 mutants with TRiC
was recapitulated in human cells, as measured by IP-western
of HA-tagged TCAB1. Despite accumulating at a lower level,
each TCAB1 mutant showed a steady-state association with
TRiC substantially greater than that of wild-type TCAB1 (Fig-
ure 6G). We used extracts from DC patient lymphoblasts to
determine whether this increased association with TRiC was
evident when TCAB1 mutants were expressed at endogenous
levels. Although TCAB1 mutant proteins were expressed at
reduced levels in DC lymphoblasts, immunoprecipitation of
endogenous mutant TCAB1 protein pulled down significantly
more TRiC compared with immunoprecipitation of wild-type
TCAB1 from healthy donor control lymphoblasts (Figure 6H).
Taken together, these data show that the TCAB1 mutant form
of DC is caused by amino acid mutations that disrupt TCAB1
folding by TRiC, providing important evidence that telomere
maintenance by telomerase is exquisitely dependent on TRiC
and that interfering with this process results in severe disease
in humans.
DISCUSSION
A Model for TRiC-Mediated Folding of TCAB1 in
Telomere Maintenance
In searching for regulators of telomerase trafficking using a
genome-wide loss-of-function high-content screen, we identi-
fied the TRiC chaperonin as a critical node in the telomerase
pathway and one whose actions are subverted in disease. Our
data support a model in which newly translated TCAB1 protein
associates with TRiC through an interaction that requires the(C) Top, dual-affinity chromatography purified AH3-TCAB1 from HeLa S3 cells,
eluate, preclear negative control step before anti-HA pull-down.
(D) Western blot for TCAB1 and TRiC subunits from co-IP of endogenous TCAB
(E) Co-IP of in-vitro-translated FLAG constructs in RRL incubated with in vitro tran
(TERC and recovery control). Bottom, schematic of each construct and degree
accumulate to detectable levels.WD40 domain of TCAB1. TRiC folds TCAB1 in the cytoplasm,
and once correctly folded, TCAB1 translocates to the nucleus
where it binds the TERC CAB box and likely associates
with dyskerin through protein-protein contacts to facilitate
localization of telomerase within Cajal bodies. This localization
step is essential for telomere maintenance, as TCAB1 is also
required for recruitment of telomerase to telomeres, a step gov-
erned by the interaction between TERT and TPP1 (Nandakumar
et al., 2012; Stern et al., 2012; Venteicher et al., 2009; Zhong
et al., 2011, 2012). Consistent with a requirement in folding
TCAB1, depletion of any TRiC subunit resulted in reduced
TCAB1 protein in Cajal bodies, mislocalization of TERC to
nucleoli, and a marked impairment of telomerase recruitment
to telomeres. TRiC is also needed for correct trafficking of
scaRNAs to Cajal bodies, as loss of TRiC resulted in inappro-
priate trafficking of scaRNAs to nucleoli. Because scaRNAs
serve as guides for the pseudouridylation of splicing RNAs,
our data suggest that, through folding TCAB1, TRiC may be
required for the assembly of splicing RNPs and perhaps for
efficient RNA splicing.
Our data indicate that TRiC-dependent folding of TCAB1
represents a third biogenesis pathway required for telomerase
function. Most well understood are the RNA-dependent steps
needed for stability, processing, and assembly of TERC. TERC
biogenesis relies on the machinery devoted to related snoRNAs,
including the dyskerin core complex, assembly factors Shq1 and
Naf1, and factors needed for RNA end processing and capping
(Figure 7, green box). Factors have also been identified that
are required for TERT accumulation and assembly into the
telomerase complex. Pontin and Reptin are AAA+ ATPases
that are required for both TERC accumulation and TERT assem-
bly into the telomerase holoenzyme (Venteicher et al., 2008).
Additionally, the molecular chaperones p23 and Hsp90 both
bind TERT, and inhibition of this interaction reduces accumula-
tion of TERT protein and blocks assembly of the telomerase cat-
alytic core (Holt et al., 1999) (Figure 7, orange box). In contrast to
these two pathways focused on the catalytic core of the enzyme,
our findings reveal a proteostasis pathway that is not essential
for the biogenesis of TERT or TERC but is critical for the folding
of TCAB1 and therefore for localization of the telomerase com-
plex in Cajal bodies (Figure 7, blue box).
TRiC-Mediated Folding of TCAB1 Is Required for
Prevention of Dyskeratosis Congenita
TRiC depletion using siRNA caused biochemical and cell
biological phenotypes similar to those seen in cells from DC
patients with missense mutations in TCAB1, including reduced
TCAB1 protein level and mislocalization of TERC to nucleoli.
Based on these similarities, we investigated the hypothesis
that the missense mutations in TCAB1, located in the
WD40 repeat domain, represent folding mutations—sequencesilver stain. Bottom, unique peptides for each protein identified by MS. IgG in
1 from HeLa S3 cells. IgG, negative control.
scribed TERC. Top, western blot (FLAG, CCT6, and GAPDH) and northern blots
of TRiC and TERC interaction. n.d., not determined because N125 did not
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Figure 5. TRiC Is Required to Fold TCAB1, Enabling TCAB1 to Bind TERC
(A) Time course of [35S]-Met-labeled actin or TCAB1 in RRL, chased with cold Met for indicated time, native PAGE. Upper, slowly migrating species. Lower,
rapidly migrating species.
(B) Immunodepletion of CCT2 from RRL extracts in which [35S]-Met-labeled proteins (GFP, actin, or TCAB1) were translated, native PAGE. IgG, negative control.
(C) Partial PK digestion of [35S]-Met-labeled proteins (GFP, actin, or TCAB1) in RRL chased with cold Met for indicated times, top. Total, undigested protein,
bottom. SDS-PAGE, top and bottom.
(D) Immunodepletion of CCT2 from RRL extracts. IgG, negative control. +bTRiC, add-back of purified bovine TRiC. Western blot for CCT1, CCT2, CCT3, and
GAPDH.
(E) Immunodepletion of CCT2 from RRL extracts (as in D) prior to translation of [35S]-Met-labeled proteins (GFP, actin, or TCAB1). Native PAGE, top. SDS-PAGE
for loading, bottom. +bTRiC, add-back of purified bovine TRiC.
(F) Co-IP of TCAB1 and TERC from RRL. Western (FLAG, GAPDH) and northern (TERC, recovery) blots from co-IP of FLAG constructs in vitro translated in
previously IgG or CCT2-immunodepleted RRL, as in (D), incubated with in-vitro-transcribed TERC. Blots were processed simultaneously and are directly
comparable.changes that disrupt the ability of TCAB1 to be correctly folded
by TRiC. Our data indicated that each patient-derived TCAB1
mutant protein failed to be released from TRiC, could not1398 Cell 159, 1389–1403, December 4, 2014 ª2014 Elsevier Inc.achieve a protease-resistant form, exhibited marked reduction
in binding TERC, and showed a significant increase in associa-
tion with TRiC. All these findings are consistent with a disruption
of TCAB1 folding by the amino acid mutations in DC patients.
Because mutant TCAB1 readily binds TRiC, we conclude that
the missense mutations disrupt the folding process itself and
that misfolded TCAB1 is eventually released and destroyed, af-
ter failing an important quality control step. Although misfolded
TCAB1 is reduced in level and is functionally impaired, it is
important to note that reduced levels of mutant TCAB1 protein
remain detectable in the nucleus and even in Cajal bodies.
These findings suggest that the folding mutations are hypomor-
phic in nature, severely impairing, but not eliminating, TCAB1
function.
Folding Mutations Yield Hypomorphic Disease Variants
in Highly Conserved Proteins
Thus far, no complete loss-of-function mutations in any telome-
rase component have been identified in DC patients, suggesting
that complete inactivation of telomerase function may be incom-
patible with viability in humans (Zaug et al., 2013). Homozygous
null mutations in TCAB1 would be even less likely, given the po-
tential importance of TCAB1 in the pseudouridylation of splicing
RNAs. The challenge in generating a telomere-disease pheno-
type lies in reducing telomeremaintenance levels below a certain
threshold, while preserving sufficient reserves in telomere main-
tenance to avoid embryonic lethality. For multifunctional pro-
teins, their functions in other pathways need to be preserved
as well. The best example is dyskerin, which is required for pseu-
douridylation of ribosomal RNAs and splicing RNAs. To avoid the
embryonic lethality of dyskerin inactivation, DCmutations in dys-
kerin are missense mutations that cluster at a particular surface
of the protein, sufficiently preserving its pseudouridylation func-
tion to allow viability, while at the same time compromising its
ability to support telomerase biogenesis (Mitchell et al., 1999;
Rashid et al., 2006; Wong and Collins, 2006). The exquisite
dependence of TCAB1 on the TRiC pathway allowed for the
emergence of TCAB1 folding mutations that accomplish this
titration of TCAB1 activity by a different means—by disrupting
TRiC-mediated folding and by globally reducing TCAB1 levels
and function. It is interesting to note that the vast majority of dis-
ease-associated mutations in TERT and TERC are point muta-
tions, which commonly preserve some residual activity. It is likely
that a significant subset of these mutations disrupt folding of
TERT protein or TERCRNA and that suchmutations would oper-
ate in similar fashion to the TCAB1 mutations in reducing the
level and activity of TERT or TERC.
The mechanisms by which mutations in other TRiC substrates
cause disease differ. Mutant huntingtin (Htt) protein generates
large aggregates, eventually overwhelming the proteostasis
network and causing proteotoxicity (Behrends et al., 2006; Kita-
mura et al., 2006; Tam et al., 2006). Instead of aggregating, VHL
mutants either prevent TRiC interaction or prevent TRiC release
(Feldman et al., 2003), the latter mechanism being similar to the
effects of the TCAB1 mutations. The identification of TCAB1 as
a TRiC substrate is surprising because TCAB1 is both nuclear
and an RNA-binding protein, which are rare among TRiC sub-
strates (Yam et al., 2008). Thus, TRiC may be responsible for
folding a larger variety of protein classes than previously
thought, expanding its potential contribution to the proteostasis
network.Proteostasis, Aging, Telomerase Function, and Disease
A dramatic decline in proteostasis has been linked to aging in
diverse organisms, and this decline drives age-related pathol-
ogies (Hartl et al., 2011; Taylor and Dillin, 2011). TRiC, specif-
ically, has been implicated in human age-related degeneration
via its interaction with the htt protein (Kitamura et al., 2006;
Tam et al., 2006). The evidence that chaperones (TRiC,
Hsp90, and p23) impinge on multiple steps of telomerase
biogenesis leads us to speculate that reduced proteostasis
with aging may lead to a decline in telomerase function, partic-
ularly because proteostatic networks tend to lack significant
excess capacity (Morimoto, 2008). Impaired telomerase func-
tion, in turn, could lead to age-related telomere dysfunction,
particularly in those tissues that depend on telomerase during
aging, such as bone marrow, gastrointestinal epithelium, skin,
liver, and lung.
Our data identify an exquisite dependence of telomerase on
TRiC, revealing that TRiC-mediated folding of TCAB1 is essential
for telomeremaintenance in human tissues and that disruption of
this process leads to dyskeratosis congenita. These findings
have important implications in understanding telomere dysfunc-
tion in aging and in human disease.
EXPERIMENTAL PROCEDURES
Cell Culture, Transfections, and Viral Transductions
HeLa S3 and 293T cells were cultured in DMEM supplemented with 10%
FBS. Lymphoblasts were cultured in RPMI 1640 supplemented with 10%
FBS. Lipofectamine 2000 (Life Technologies, 11668019) was used for all
cDNA transfection experiments. Dharmafect 4 (Thermo, T-2004-01) was
used for all siRNA transfections. All siRNAs were siGENOME pools purchased
from Dharmacon/Thermo and used at 25 or 50 nM. Cells were assayed 72 hr
after transfection. For transduction, 293T cells were transfected with the
appropriate target plasmid and packaging constructs (lentiviral or retroviral)
overnight; 48 hr later, viral supernatant was collected. Cells were transduced
in the presence of 5 mg/ml Polybrene and selected for 3–7 days depending on
the selection marker.
Western and Northern Blotting
Cells were lysed in NP40 buffer (25 mM HEPES-KOH, 150 mM KCl, 1.5 mM
MgCl2, 0.5%NP40, 10%Glycerol [pH 7.5]) supplemented with protease inhib-
itors (Roche, 11836153001) for 20 min on ice. Lysate was clarified by centrifu-
gation at 16,000 3 g for 10 min and quantified by BCA assay (Pierce, 23225).
For western blotting, 10–50 mg was separated by SDS-PAGE, transferred onto
PVDF membrane (GE Healthcare, RPN303F), and blotted according to stan-
dard protocols. 5% milk in TBST (0.1% Tween) was used for all blocking
and antibody incubation steps; TBST (0.1% Tween) was used for all washes.
For northern blotting, RNA was extracted with TRIzol (Life Technologies,
15596-026), separated using 5% urea TBE gel electrophoresis, transferred
onto Hybond-N membrane (GE Healthcare, RPN303N), and hybridized with
ULTRAhyb (Ambion, AM8670). TERC probe was generated by random body
labeling with full-length TERC cDNA.
TERC In Vitro Binding Assays
TERC or TERC mutant RNA (m1, m2) was in vitro transcribed (IVT) using the
MEGAScript T7 kit (Life Technologies, AM1334). Target DNA was PCR
amplified with a minimal T7 promoter at the 50 end, and 240 ng of each PCR
product was used in the transcription reaction. The reaction was incubated
for 6 hr at 37C, and RNAwas purified using TRIzol reagent (Life Technologies,
15596-026). In vitro transcription/translation of TCAB1 or TCAB1 mutants is
described in detail in the ‘‘In Vitro Transcription/Translation’’ section; RRL re-
action was incubated for 2 hr at 30C, and then 1 mg IVT RNA was added and
the reaction was incubated for another 2 hr at 30C. The reaction was diluted inCell 159, 1389–1403, December 4, 2014 ª2014 Elsevier Inc. 1399
Figure 6. Disruption of TRiC-Mediated Folding Underlies the Defects in the TCAB1 Mutant Form of DC
(A) Schematic of TCAB1 domains and DC-associated mutations.
(B)Western blots of endogenous TCAB1 from control or DCpatient-derived lymphoblasts (left) or stably overexpressedHA-tagged TCAB1 (wild-type or individual
mutants) from HeLa S3 cells (right).
(legend continued on next page)
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Figure 7. Model of Telomerase Biogenesis
and Trafficking
Three arms of telomerase holoenzyme biogenesis
(TCAB1, TERT, and TERC) undergo independent
and essential biogenesis steps before being
assembled into active telomerase. Curved arrows,
factors transiently associated. Curved lines, fac-
tors permanently associated. Red text, processes
mediated by the listed factors. Factors are not
necessarily listed in chronological order and are
not all inclusive.500 ml of NP40 buffer (see ‘‘Western Blotting’’ section), and FLAG immunopre-
cipitation was performed as described in ‘‘Immunoprecipitations and Immuno-
depletions.’’ RNA was analyzed by northern blotting.
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